JPRN-UMIN000014395已完成1 期
An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosis - An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with cirrhosis due to causes other than hepatitis C virus; or patients with cirrhosis due to unknown causes. (2)Patients with a history of primary liver cancer or a complication thereof. (3)Patients with a complication of malignant tumor or a history thereof (within 5 years prior to screening). (4)Patients in whom such active viral infections as HBV, HIV or ATCL or syphilis infection cannot be ruled out. (5)Patients with serum creatinine >1.5 times over upper normal or creatinine clearance =<60 mL/min/1.73 m2. (6)Patients with hemoglobin <8 g/dL. (7)Patients with platelet count <50,000 /µL. (8)Patients with T.Bil =>3.0 mg/dL. (9)Patients with a complication of poorly controlled diabetes, hypertension or heart failure. (10)Patients with a complication of mental disorder requiring treatment. (11)Patients with serious allergy to contrast media or a history thereof. (12)Patients with allergy to inactive ingredients of the study drug. (13)Patients who have received interferon, ribavirin or anti-HCV agents within 12 weeks before registration in this study. (14)When the medical treatment to a primary disease is carried out, Patient who was changed the dosage and administration within the 12 weeks before registration. (15)Patients with a history of drug or alcohol addiction within five years at the time of providing written consent or a history of drug or alcohol abuse within the past one year. (16)The patient who received a liver transplant or other organ transplants (a bone marrow transplantation is included), and the patient for whom intravenous administration and venous access are difficult. (17)Patients contraindicated for liver biopsy. (18)Female patients who are pregnant or suspected to be pregnant; or those who desire to get pregnant during the study period or those of childbearing potential. (19)Male patients who do not consent to practice birth control during the clinical study.
研究者
相似试验
已完成
1 期
A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of EARLI-001 in subjects with lung cancerLung cancerACTRN12620001178932Earli, Pty Ltd10
已完成
1 期
A clinical trial to assess the safety of new erythropoietin in chronic kidney disease patients on Haemodialysis.CTRI/2011/11/002153Serum Institute of India Pvt Ltd40
已完成
1 期
study to determine safety, tolerability and pharmacokinetics of Ursodiol injection 625mg/25ml (25mg/ml)CTRI/2023/04/051381Shilpa Medicare Limited30
终止
1 期
A Phase I Open-Label, Single Dose, Dose Escalation Study of KB002, a Chimeric Monoclonal Antibody Which Binds to GM-CSF (Granulocyte Macrophage Colony Stimulating Factor), in Patients with Chronic Idiopathic Thrombocytopenia Purpura (ITP)Idiopathic Thrombocytopenia Purpura (ITP)Blood - Other blood disordersACTRN12606000459527KaloBios Pharmaceuticals Inc27
招募中
1 期
A Phase I clinical trial evaluating the Safety, Tolerability, and Efficacy of Oral AUR107 in Patients with Advanced CancerCTRI/2023/05/052954Aurigene Oncology Limited